Moderna's RSV Vaccine Shows 81.8% Protection Against Hospitalization in Older Adults

Source Summary

A single dose of Moderna's mResvia RSV vaccine demonstrated 60.3% effectiveness against documented RSV infections and 60.2% against RSV-related emergency or urgent care visits in older U.S. veterans, according to findings published in JAMA Network Open. The vaccine showed 81.8% protection against RSV-associated hospitalizations in the population aged 50 and older.

Why it matters

The high protection rate against RSV hospitalization addresses a significant health risk in older adults, a population vulnerable to severe respiratory illness.

Read the Source

• Medical Xpress ↗